QIAGEN Expands the QIAcuity Portfolio
QIAGEN has just made an exciting announcement: they’re adding over 100 new assays to their QIAcuity digital PCR platform. This important development boosts their capabilities across various sectors—including cancer research, genetic disorders, infectious disease monitoring, and environmental studies. These new assays are accessible through the GeneGlobe platform, combining cutting-edge technology with a wealth of biological resources that aid researchers and healthcare professionals.
Key Features of the GeneGlobe Platform
The GeneGlobe platform is more than just a home for these new assays; it also features a vast database with over 10,000 biological entities, including genes, miRNAs, and several pathways. This comprehensive integration enhances the precision and efficiency of molecular diagnostics, providing scientists with pre-designed assays tailored for their unique research requirements.
Ongoing Growth and Success
In 2024 alone, QIAGEN has exceeded its initial targets by launching more than 130 new assays, bringing the impressive total to over 2,300 validated assays in its portfolio. Nitin Sood, Senior Vice President at QIAGEN, highlighted the company’s dedication to addressing customer needs and advancing the QIAcuity platform's capabilities.
Prominent Applications and Benefits
The newly launched assays feature potent options such as:
- dPCR LNA Mutation and dPCR CNV Probe Assays, which focus on critical mutations relevant to cancer and changes in copy numbers of specific DNA sequences. They’re especially beneficial for analyzing colorectal cancer, sarcomas, and thyroid cancer.
- dPCR Microbial DNA Detection Assays that pinpoint key pathogens linked to infectious diseases, such as those causing urinary tract infections, while also tackling issues of microbial resistance and plant pathogens affecting agriculture.
Strong Market Demand
The QIAcuity digital PCR system has seen widespread adoption, with over 2,000 installations reported by the end of 2023. This includes a notable presence in more than 450 publications. Its users range from pharmaceutical companies and academic institutions to diagnostic centers and forensic labs, highlighting the versatile applications of the QIAcuity system.
The Future of QIAcuity in Clinical Testing
Looking to the future, QIAGEN plans to extend the QIAcuity platform into clinical testing. An in-vitro diagnostic variant is set to launch in the fall of 2024. This version will play a vital role in diagnosing infectious diseases and tracking cancer progression using less invasive liquid biopsies. QIAGEN is also working closely with pharmaceutical companies to create companion diagnostics that utilize the platform's strong sensitivity and accuracy.
About QIAGEN
Based in the Netherlands, QIAGEN N.V. is recognized as a global leader in Sample to Insight solutions. The company aims to empower its customers by delivering valuable molecular insights from their samples. QIAGEN's technologies efficiently isolate and analyze nucleic acids and proteins, serving a diverse clientele exceeding 500,000 clients worldwide. As of mid-2024, QIAGEN employs over 5,900 individuals across 35 locations, underscoring its strong global footprint.
Frequently Asked Questions
What are the primary applications of the new QIAcuity assays?
The new assays target areas like cancer research, genetic disorders, infectious disease monitoring, and environmental analysis.
How does the GeneGlobe platform enhance research capabilities?
GeneGlobe combines pre-designed assays with a large database of biological entities, allowing for more precise analysis and improving research efficiency.
What future developments can we expect from QIAGEN's QIAcuity platform?
QIAGEN plans to launch an in-vitro diagnostic version of QIAcuity, providing support for clinical applications such as disease diagnosis and cancer monitoring.
Who are the primary users of the QIAcuity digital PCR system?
The system is widely used by pharmaceutical companies, academic institutions, diagnostic centers, and forensic labs, showcasing its broad applicability.
How many assays are currently available on the QIAcuity platform?
With the recent expansion, QIAGEN now offers more than 2,300 validated assays on the QIAcuity platform.
